Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Summit Therapeutics Inc. - Common Stock
(NQ:
SMMT
)
17.52
+0.03 (+0.17%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Summit Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
June 25, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
June 24, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
June 23, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Smart Money is Quietly Loading Up On This $160M Oncology Stock — Is Nuvectis Pharma the Next Breakout Biotech? (NASDAQ: NVCT)
June 20, 2025
With clinical catalysts on the horizon and a seasoned biotech insider doubling down, Could Nuvectis Pharma (NASDAQ:NVCT)* Become the Next Summit Therapeutics (NASDAQ: SMMT)?
Via
News Direct
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
June 20, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
June 18, 2025
From
Pomerantz LLP
Via
GlobeNewswire
2 Dividend Stocks to Buy and Never Sell
↗
June 18, 2025
Via
The Motley Fool
Topics
Lawsuit
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
June 15, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Why Summit Therapeutics Stock Tanked Today
↗
June 11, 2025
Via
The Motley Fool
This Coinbase Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
↗
June 11, 2025
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
June 10, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Why Casey's General Stores Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
↗
June 10, 2025
Via
Benzinga
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2025
From
Summit Therapeutics Inc.
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
June 06, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
June 05, 2025
From
Summit Therapeutics Inc.
Via
Business Wire
2 Soaring Stocks Wth More Upside Potential
↗
June 05, 2025
Via
The Motley Fool
3 No-Brainer Healthcare Stocks to Buy in June
↗
June 02, 2025
Via
The Motley Fool
Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy?
↗
June 02, 2025
Via
The Motley Fool
Temu Parent PDD, Regeneron Pharmaceutical And Burlington Stores Are Among Top 11 Large-Cap Losers Last Week (May 26-May 30): Are The Others In Your Portfolio?
↗
June 01, 2025
11 large-cap stocks with worst performance in last week: SMMT, PDD, REGN, BAH, OKTA, DECK, CPRT, COO, TPL, HPQ, BURL. Mixed results, lowered forecasts.
Via
Benzinga
Which stocks are experiencing notable movement on Friday?
↗
May 30, 2025
Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session.
Via
Chartmill
Dow Edges Higher; Dell Shares Fall After Q1 Results
↗
May 30, 2025
Via
Benzinga
Topics
Stocks
Why Summit Therapeutics Plunged Today
↗
May 30, 2025
Via
The Motley Fool
12 Health Care Stocks Moving In Friday's Intraday Session
↗
May 30, 2025
Via
Benzinga
Top movers in Friday's session
↗
May 30, 2025
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via
Chartmill
Summit Therapeutics Stock Tumbles On Oncology Drug Trial Data, Retail Flags ‘Insane’ Valuation
↗
May 30, 2025
Summit now intends to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration seeking approval for Ivonescimab plus chemotherapy based on the results of the trial.
Via
Stocktwits
Topics
Lawsuit
Regulatory Compliance
Traders are paying attention to the gapping stocks in Friday's session.
↗
May 30, 2025
Traders are paying attention to the gapping stocks in Friday's session. Let's dive into which stocks are experiencing notable gaps.
Via
Chartmill
Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure
↗
May 30, 2025
There's a long history of anti-PD-1 and anti-VEGF drugs working to slow progression, but not improve overall survival.
Via
Investor's Business Daily
Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint
↗
May 30, 2025
Summit Therapeutics' Phase 3 trial met the primary goal in lung cancer, showing significant PFS benefit with ivonescimab plus chemotherapy.
Via
Benzinga
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study
May 30, 2025
From
Summit Therapeutics Inc.
Via
Business Wire
3 High-Flying Stocks That Could Soar Even More
↗
May 24, 2025
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
